Physician profile
Mark H Rubenstein
NPI 1457397580
$14,387.44
in general payments reported to CMS, 2019-2025
39 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $1,311 · 2021: $1,562 · 2022: $2,307 · 2023: $2,018 · 2024: $2,601 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,000.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,855.36 | 2019-2025 | |
| Abbott Laboratories | $1,537.91 | 2019-2025 | Aveir, Jot Dx, Confirm Rx |
| Janssen Pharmaceuticals, INC | $1,438.24 | 2019-2024 | Xarelto |
| Amgen INC. | $1,327.93 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,288.32 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,127.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $765.32 | 2019-2025 | Farxiga, Wainua |
| Amarin Pharma, INC. | $602.34 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $518.81 | 2021-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $470.11 | 2021-2025 | Micra, Linq II, Aurora Ev-Icd Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $461.72 | 2020-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $394.18 | 2019-2024 | |
| Philips North America LLC | $322.77 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Boston Scientific Corporation | $306.44 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.31 | 2020-2025 | Lifevest |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.